Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis-Reference-Cited by-同舟云学术

Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis

Published:2016-07-21 Issue:11 Volume:1 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Cinar Resat,Iyer Malliga R.,Liu Ziyi,Cao Zongxian,Jourdan Tony,Erdelyi Katalin,Godlewski Grzegorz,Szanda Gergő,Liu Jie,Park Joshua K.,Mukhopadhyay Bani,Rosenberg Avi Z.,Lieow Jeih-San,Lorenz Robin G.,Pacher Pal,Innis Robert B.,Kunos George

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference70 articles.

1. Pathobiology of liver fibrosis: a translational success story

2. Polypharmacology in a Single Drug: Multitarget Drugs

3. Advances in antifibrotic therapy

4. Modulating the endocannabinoid system in human health and disease - successes and failures

5. The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of mitochondria in pathogenesis and therapy of renal fibrosis;Metabolism;2024-06

2. Pharmacological Evaluation of Cannabinoid Receptor Modulators Using GRABeCB2.0 Sensor;International Journal of Molecular Sciences;2024-05-03

3. Potential therapeutic medicines for renal fibrosis: Small-molecule compounds and natural products;Bioorganic Chemistry;2024-02

4. In vitro and in vivo pharmacokinetic characterization, chiral conversion and PBPK scaling towards human PK simulation of S-MRI-1867, a drug candidate for Hermansky-Pudlak syndrome pulmonary fibrosis;Biomedicine & Pharmacotherapy;2023-12

5. Cannabinoformins: Designing Biguanide-Embedded, Orally Available, Peripherally Selective Cannabinoid-1 Receptor Antagonists for Metabolic Syndrome Disorders;Journal of Medicinal Chemistry;2023-08-23